Drugs / SafeTynadol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT03451487 | May → Dec 2022 | paracetamol poisoning | Sinew Pharma Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05842733 Comparator | Jul 2023 → Dec 2024 | neuropathy, painful | Sinew Pharma Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-16 | Sinew Pharma Inc. | Results 川普引爆乙醯胺酚安全疑慮 欣耀SafeTynadol搶攻孕期止痛新藍海 sinewpharma.com ↗
根據臨床試驗數據，即使在 3 倍高劑量下， NAPQI 相關的肝臟毒性指標（ APAP-Cys 蛋白複合物）幾乎測不到，也未出現肝腎毒性或嚴重副作用。 |
| 2024-06-06 | Sinew Pharma Inc. | Results 欣耀生醫止痛新藥完成臨床試驗 目標取代現有市場 sinewpharma.com ↗
此結果證實SNP-810在臨床上使用劑量達現行乙醯胺酚藥品說明書最大允許劑量的三倍，是肝安全性高的止痛藥。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-16 | Sinew Pharma Inc. | 川普引爆乙醯胺酚安全疑慮 欣耀SafeTynadol搶攻孕期止痛新藍海 sinewpharma.com ↗ |
| 2024-06-06 | Sinew Pharma Inc. | 欣耀生醫止痛新藥完成臨床試驗 目標取代現有市場 sinewpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SafeTynadol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03451487 ↗ |
| Route | Oral | “will be orally administered” NCT03451487 ↗ |